On October 23, 2026, Bolt Biotherapeutics,  a clinical-stage biotechnology company, announced the acquisition of Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, Bolt Biotherapeutics will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned. Wilson Sonsini Goodrich & Rosati advised Prana Therapies on the intellectual property matters related to the transaction.

The Wilson Sonsini team that advised Prana on IP matters related to the transaction included Derrick Rowe, Michael Hostetler, Inyoung Choi, and Sebastian Kamau.

For more information, please see Bolt Biotherapeutics’ news release. Additional information can be found on Fierce Biotech.